ClinicalTrials.gg
Not yet recruitingNCT07950488ATTENTIONUpdated Nov 20, 2026

Clinical Characteristics and Long-Term Outcomes of Patients With Valvular Heart Disease

An observational study in Heart Valve Diseases, Aortic Valve Disease and Mitral Valve Disease, sponsored by First Affiliated Hospital Xi'an Jiaotong University. Not yet recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-20.

Primary conditionAortic Valve DiseaseRegistry: Heart Valve DiseasesReclassifiedWhy we changed it
Registry
Heart Valve Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Aortic Valve Disease
Why
  1. The study's listed conditions name Aortic Valve Disease, a narrower term within Heart Valve Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Observational

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
15,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 27 studies in Aortic Valve Disease with a site in China — 16 open to participants now, 18 under way, none of them phase 3. Aortic Valve Disease · China.

Planned enrollment
Largest of 13
15,000 · median 1,000
Started
2026
with 3 others
Observational
13 of 27
10 open now
Primary completion
2050-12
later than 17 of 17 live
Registered
27th of 27
by date
Lead sponsor
1 of 27
First Affiliated Hospital Xi'an Jiaotong University

Among the 27 studies in Aortic Valve Disease with a site in China, this one has the largest planned enrollment of the 13 observational ones that give a count, is one of 4 that started in 2026, is one of 13 observational ones, reaches primary completion later than 17 of the 17 other live ones, and was the 27th registered.

Aortic Valve Disease

235 studies on the registry are indexed under Aortic Valve Disease; 71 are open to participants now.

Browse Aortic Valve Disease studies →

Open to participants now

16 of the 27 studies in Aortic Valve Disease with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 46 Aortic Valve Disease studies recruiting now, 34 (74%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Aortic Valve Disease with a site in China, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about the clinical characteristics, natural course, and long-term outcomes of valvular heart disease in children and adults of all ages. The main questions it aims to answer are:

  • How many participants die from any cause or are hospitalized for heart failure within 5 years?
  • How does valvular heart disease change over time, and how do different causes, severity levels, other medical conditions, and treatments affect long-term outcomes?

Participants with valvular heart disease will:

  • Receive their regular medical care, which may include medications, surgery, or catheter-based procedures (the study does not change any treatment)
  • Have their medical records, laboratory tests, and heart imaging results collected
  • Attend follow-up visits at 6 months, 12 months, and then once a year
  • Be asked to provide extra blood samples during routine blood draws, and leftover valve or heart tissue from clinically indicated procedures, only if they agree (this is optional)
Read the detailed description

The ATTENTION study is a national, multicenter, observational registry cohort study of patients with valvular heart disease (VHD), led by the First Affiliated Hospital of Xi'an Jiaotong University in collaboration with multiple medical centers across China. The study does not assign any intervention and does not alter routine clinical care. It aims to establish a long-term research platform integrating a clinical database, a longitudinal follow-up cohort, and a standardized biospecimen repository, to characterize clinical phenotypes, the natural history, treatment pathways, cardiac remodeling, and long-term outcomes across the full spectrum of VHD.

The cohort includes a retrospective component and a prospective component. The retrospective cohort comprises eligible patients identified from electronic medical records, laboratory and imaging databases, surgical and interventional records, pathology archives, and existing follow-up records between January 1, 2013 and the date of ethics approval of the amended protocol. The prospective cohort continuously enrolls patients after ethics approval of the amended protocol through December 31, 2045. Each participant is followed for at least 5 years in principle, with overall follow-up planned through December 31, 2050, at 6 months, 12 months, and annually thereafter, supplemented by routine outpatient, inpatient, and telephone follow-up.

Eligible participants are patients of any age and either sex with a confirmed clinical diagnosis of VHD involving the aortic, mitral, tricuspid, or pulmonary valve, or multiple valves, of any etiology (degenerative, rheumatic, congenital, infective, or functional/secondary), any severity, and any treatment status (conservative management, surgical repair or replacement, or transcatheter intervention). Patients with prior valve intervention are not excluded; the date, type, and baseline valve function of prior treatment are recorded. Cohort baseline is defined as the first visit during the observation period at which eligibility criteria are met and core clinical information is available. Events occurring before baseline are distinguished from incident events during follow-up.

Data collected include demographics; etiology, location, and severity of valve disease; cardiac structure and function (echocardiography, and cardiac magnetic resonance, computed tomography, or catheterization when available); comorbidities; laboratory tests; treatments and their changes over time; and clinical events. Stratified analyses are performed by valve involved, etiology, severity and clinical stage, and treatment pathway.

The primary outcome is the first occurrence of all-cause death or hospitalization for heart failure within 5 years of cohort baseline. Secondary outcomes include cardiovascular death; progression of valve disease; first valve intervention; valve reintervention; prosthetic valve- or repair-related complications (adjudicated per applicable consensus standards, including VARC-3); other major cardiovascular events (stroke, systemic thromboembolism, severe arrhythmias, cardiac arrest, cardiogenic shock); repeated heart failure hospitalizations and unplanned cardiovascular hospitalizations; and perioperative or periprocedural outcomes at 30 days, during hospitalization, and at 1 year after valve intervention.

A biospecimen repository is nested within the cohort on a voluntary basis. Research blood samples are collected only as an additional volume at the time of clinically indicated blood draws; valve, myocardial, vascular, and other tissues are collected only as leftover material after clinical and pathological needs are met. Biospecimen collection is not a condition for enrollment or continued follow-up. Molecular and multi-omics analyses of stored samples may be performed in future separately approved substudies.

Statistical analyses include descriptive statistics, Kaplan-Meier estimates, and Cox proportional hazards models, with competing-risk methods for non-fatal outcomes, time-dependent variables for treatments occurring during follow-up, mixed-effects or recurrent-event models for longitudinal and repeated data, and multivariable adjustment accounting for multicenter clustering. The overall cohort size is anticipated to be at least 15,000 participants; formal sample size calculation is not applicable because the registry aims to describe clinical phenotypes and long-term outcomes rather than to test a specific treatment effect.

03

Conditions studied

  • Heart Valve Diseases
  • Aortic Valve Disease
  • Mitral Valve Disease
  • Tricuspid Valve Disease
  • Pulmonary Valve Disease

Keywords

  • valvular heart disease
  • aortic stenosis
  • aortic regurgitation
  • mitral regurgitation
  • tricuspid regurgitation
  • rheumatic heart disease
  • transcatheter valve intervention
  • heart failure hospitalization
  • long-term outcomes
  • biobank
04

In context

Aortic Valve Disease Reclassified

235 studies on the registry are indexed under Aortic Valve Disease; 71 are open to participants now.

This study's planned enrollment of 15,000 is above the median of 200 across 107 observational studies indexed under Aortic Valve Disease.

Browse Aortic Valve Disease studies →

Lead sponsor

First Affiliated Hospital Xi'an Jiaotong University is the lead sponsor of 318 studies on the registry; 91 are open to participants now.

Compared within Aortic Valve Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Valve Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population comprises patients of all ages with clinically diagnosed valvular heart disease, including aortic, mitral, tricuspid, pulmonary, and multiple valvular diseases, receiving routine medical care at participating centers in China. Patients may receive conservative management, surgical valve repair or replacement, or transcatheter interventions. The retrospective cohort includes eligible patients identified from existing medical records beginning January 1, 2013. The prospective cohort includes patients enrolled following ethics approval of the amended protocol. Patients with relevant cardiovascular or noncardiovascular comorbidities are eligible. Biospecimen availability is not required for participation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients of any age and sex with a clinically established diagnosis of valvular heart disease (VHD), including aortic, mitral, tricuspid, pulmonary, or multiple valvular diseases.
  2. Diagnosis of VHD confirmed by treating physicians based on medical history, clinical examination, echocardiography, and other relevant diagnostic findings, according to applicable clinical guidelines and consensus recommendations.
  3. Availability of sufficient clinical information to confirm the diagnosis of VHD, establish the cohort baseline, and characterize essential clinical features.
  4. Fulfillment of applicable ethical and requirements for the relevant study activities, including approved consent waivers where appropriate.

Exclusion criteria

Exclusion Criteria:

  1. Inability to establish a diagnosis of VHD or insufficient essential clinical information to determine the cohort baseline and key clinical characteristics.
  2. Isolated physiological trivial valvular regurgitation without evidence of clinically significant structural or functional valvular disease.
  3. Explicit refusal of the relevant study activities or use of clinical data when no other legally and ethically applicable basis for data use exists.
  4. Ineligibility for the relevant study activities due to applicable legal, ethical, or institutional research requirements.

Additional Considerations:

Patients will not be excluded solely because of advanced age, pediatric status, coexisting congenital heart disease, coronary artery disease, cardiomyopathy, heart failure, chronic kidney disease, or other comorbidities.

The availability of biospecimens is not required for enrollment or continued participation. Patients who decline biospecimen collection, have no available specimens, or miss an individual follow-up assessment will not automatically be excluded from the clinical registry. Collection and use of biospecimens are subject to separate applicable consent and ethics approval requirements.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
15,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Retrospective Cohort

    Patients with clinically diagnosed valvular heart disease identified from existing medical records between January 1, 2013, and the date of ethics approval of the amended protocol. Historical clinical characteristics, treatments, and available follow-up outcomes will be collected retrospectively.

  • Prospective Cohort

    Patients with clinically diagnosed valvular heart disease enrolled after ethics approval of the amended protocol. Clinical information and long-term outcomes will be collected prospectively through routine medical care and follow-up, with recruitment continuing through December 31, 2045.

07

What researchers measure

Primary outcomes

  1. Time to First All-Cause Death or Unplanned Hospitalization for Heart Failure

    Time from cohort baseline to the first occurrence of all-cause death or unplanned hospitalization for heart failure, whichever occurs first. Heart failure hospitalization is defined as an unplanned admission for new or worsening heart failure, confirmed by clinical assessment and requiring heart failure-directed treatment. Elective admissions and routine postoperative observation without worsening heart failure are excluded. The outcome will be reported as the time to the first composite event, measured in days, with the cumulative event probability assessed through 5 years.

    Time frame: From baseline through 5 years

Secondary outcomes

  1. Cardiovascular Mortality

    Time from cohort baseline to death attributed to a cardiovascular cause, including heart failure, myocardial infarction, fatal arrhythmia, stroke, or valvular heart disease-related complications. The date and cause of death will be determined from available medical records, death documentation, and follow-up information. The outcome will be reported as time to cardiovascular death in days and cumulative incidence through 5 years.

    Time frame: From baseline through 5 years

  2. Percentage of Participants With Progression of Valvular Heart Disease

    Percentage of participants with documented progression of valvular heart disease during follow-up. Progression is defined as worsening of the severity grade of stenosis or regurgitation in at least one affected valve, based on serial echocardiography and applicable guideline-based criteria. Each participant will be counted once upon the first documented progression. The denominator will include participants with sufficient baseline and follow-up assessments to evaluate progression.

    Time frame: From baseline through 5 years

  3. Percentage of Participants Undergoing First Valvular Intervention

    Percentage of eligible participants undergoing a first therapeutic intervention on a valve without previous intervention at baseline. Interventions include surgical valve repair or replacement, transcatheter valve repair or replacement, or another therapeutic valvular procedure. Eligibility will be determined separately for each affected valve. The first qualifying intervention date will be recorded, and each participant will be counted once for this outcome.

    Time frame: From baseline through 5 years

  4. Percentage of Participants Undergoing Repeat Valvular Intervention

    Percentage of participants undergoing repeat surgical or transcatheter intervention on a previously treated valve because of valve dysfunction, recurrent disease, infection, or another established clinical indication. The denominator will include participants with a previously treated valve who are observed during follow-up. The first qualifying repeat intervention will be counted once per participant.

    Time frame: From baseline through 5 years

  5. Percentage of Participants With Prosthetic Valve or Valve Repair-Related Complications

    Percentage of participants with at least one clinically documented prosthetic valve or valve repair-related complication during follow-up. The composite event includes valve thrombosis, structural valve dysfunction, nonstructural valve dysfunction, paravalvular leak, or prosthetic valve infective endocarditis. Each participant will be counted once if any qualifying complication occurs. The denominator will include participants with a prosthetic valve or previous valve repair.

    Time frame: From baseline through 5 years

  6. Percentage of Participants With Stroke

    Percentage of participants experiencing at least one clinically diagnosed stroke during follow-up. Stroke will be identified from medical records and neurological assessments, supported by brain imaging when available. The date of the first qualifying stroke will be recorded. Each participant will be counted once regardless of the number of subsequent strokes.

    Time frame: From baseline through 5 years

  7. Percentage of Participants With Systemic Thromboembolism

    Percentage of participants experiencing at least one clinically documented systemic arterial thromboembolic event, excluding stroke, during follow-up. Events will be confirmed using clinical records, imaging examinations, or relevant procedural documentation. Each participant will be counted once upon the first qualifying event.

    Time frame: From baseline through 5 years

  8. Percentage of Participants With Clinically Significant Cardiac Arrhythmias

    Percentage of participants with at least one clinically significant atrial or ventricular arrhythmia documented during follow-up. Events must be supported by electrocardiography, ambulatory monitoring, implantable cardiac device recordings, or hospital documentation and require clinical assessment or treatment. The measure will be reported as the percentage of participants with any qualifying arrhythmia, with each participant counted once.

    Time frame: From baseline through 5 years

  9. Percentage of Participants Experiencing Cardiac Arrest

    Percentage of participants experiencing at least one documented cardiac arrest during follow-up, identified through emergency care, hospitalization, resuscitation, or other clinical records. Both fatal and nonfatal cardiac arrest events will be included. Each participant will be counted once upon the first documented event.

    Time frame: From baseline through 5 years

  10. Percentage of Participants Developing Cardiogenic Shock

    Percentage of participants with at least one episode of clinically diagnosed cardiogenic shock during follow-up. Events will be identified from hospital records documenting circulatory failure attributed to cardiac dysfunction and associated clinical management. Each participant will be counted once upon the first qualifying episode.

    Time frame: From baseline through 5 years

  11. Number of Heart Failure Hospitalizations per Participant

    Total number of unplanned hospital admissions for new or worsening heart failure per participant during follow-up, including recurrent admissions after the first event. Each qualifying hospitalization will be counted as one event. Admission dates and reasons will be verified from available clinical records. The outcome will be reported as the number of heart failure hospitalizations per participant.

    Time frame: From baseline through 5 years

  12. Number of Unplanned Cardiovascular Hospitalizations per Participant

    Total number of unplanned hospital admissions for cardiovascular causes per participant during follow-up, including admissions for worsening heart failure, acute coronary syndromes, arrhythmias, stroke, or other clinically established cardiovascular conditions. Each qualifying hospitalization will be counted once. The outcome will be reported as the number of unplanned cardiovascular hospitalizations per participant.

    Time frame: From baseline through 5 years

  13. All-Cause Mortality Within 30 Days After Valvular Intervention

    Percentage of participants who die from any cause within 30 days after a surgical or transcatheter valvular intervention. The denominator will include participants undergoing a qualifying intervention. Death will be verified using medical records, death documentation, and available follow-up information. The date of the intervention will serve as the time origin.

    Time frame: From valvular intervention through postoperative day 30

  14. Stroke Within 30 Days After Valvular Intervention

    Percentage of participants experiencing a clinically diagnosed stroke within 30 days after surgical or transcatheter valvular intervention. Stroke will be assessed using documented neurological findings and brain imaging when available. Each participant will be counted once if a qualifying stroke occurs within the specified period.

    Time frame: From valvular intervention through postoperative day 30

  15. Major Bleeding Within 30 Days After Valvular Intervention

    Percentage of participants experiencing clinically documented major bleeding within 30 days after surgical or transcatheter valvular intervention. Events will be identified from medical records and adjudicated using the applicable prespecified bleeding criteria for the procedure. Each participant will be counted once if at least one qualifying major bleeding event occurs.

    Time frame: From valvular intervention through postoperative day 30

  16. Acute Kidney Injury Within 7 Days After Valvular Intervention

    Percentage of participants developing acute kidney injury within 7 days following surgical or transcatheter valvular intervention, identified using available serum creatinine measurements and clinical documentation according to applicable Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Each participant will be counted once if acute kidney injury is documented during the specified period.

    Time frame: From valvular intervention through postoperative day 7

  17. Permanent Pacemaker Implantation Within 30 Days After Valvular Intervention

    Percentage of participants undergoing new permanent pacemaker implantation within 30 days after surgical or transcatheter valvular intervention. Participants with a permanent pacemaker already implanted before the index procedure will be excluded from the denominator. Pacemaker implantation will be confirmed from procedural and medical records.

    Time frame: From valvular intervention through postoperative day 30

  18. Repeat Cardiac Surgery Within 30 Days After Valvular Intervention

    Percentage of participants requiring unplanned repeat cardiac surgery within 30 days after surgical or transcatheter valvular intervention. Reoperations will be identified from surgical and hospitalization records. Each participant will be counted once if at least one qualifying unplanned reoperation occurs during the specified period.

    Time frame: From valvular intervention through postoperative day 30

  19. All-Cause Mortality Within 1 Year After Valvular Intervention

    Percentage of participants who die from any cause within 1 year after surgical or transcatheter valvular intervention. The denominator will include participants undergoing a qualifying intervention. Deaths will be identified from medical records, available death documentation, and follow-up information. The intervention date will serve as the time origin.

    Time frame: From valvular intervention through 1 year

  20. Change From Baseline in Left Ventricular Ejection Fraction

    Change in left ventricular ejection fraction (LVEF), measured by clinically performed transthoracic echocardiography. LVEF is expressed as a percentage. Change from baseline will be calculated as the follow-up LVEF minus baseline LVEF and reported in percentage points. Measurements will be obtained from available routine clinical echocardiographic examinations without study-mandated imaging.

    Time frame: Baseline, 6 months, 12 months, and annually through 5 years, as available

Other outcomes

  1. Percentage of Participants With Biospecimens Linked to Clinical and Follow-up Data

    Percentage of enrolled participants with at least one retained biospecimen linked to baseline clinical information and available follow-up data. Eligible biospecimens include blood, approved body fluids, and residual valvular, myocardial, vascular, or other relevant tissues obtained during routine clinical care with appropriate authorization. Each participant will be counted once regardless of the number or types of specimens available. The denominator will be the total number of enrolled participants. Biospecimen collection is optional.

    Time frame: From baseline through 5 years

08

Study locations

1 site
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2050, 288 months later.

Of 47 non-industry observational studies under Aortic Valve Disease, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 147. This study's planned 288 months is above that.

Counting every sponsor, half of 56 studies reached it within 49 months; a quarter within 23 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2026
First posted
Nov 20, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 31, 2050
CompletionEst.
Dec 31, 2050
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07950488
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 31, 2050 (estimated)
Completion
Dec 31, 2050 (estimated)
Last update
Nov 20, 2026

Study contacts

Guoliang Li
Contact
guoliangli@xjtu.edu.cn
0086-2985323868

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion